AmerisourceBergen Increases Dividend 17 Percent

VALLEY FORGE, Pa.–(BUSINESS WIRE)–The Board of Directors of AmerisourceBergen Corporation (NYSE: ABC)
today increased the Company’s quarterly dividend rate 17 percent to
$0.34 per common share from $0.29 per common share.

The quarterly dividend of $0.34 per common share will be payable
December 1, 2015, to stockholders of record at the close of business on
November 16, 2015.

About AmerisourceBergen

AmerisourceBergen is one of the largest global pharmaceutical sourcing
and distribution services companies, helping both healthcare providers
and pharmaceutical and biotech manufacturers improve patient access to
products and enhance patient care. With services ranging from drug
distribution and niche premium logistics to reimbursement and
pharmaceutical consulting services, AmerisourceBergen delivers
innovative programs and solutions across the pharmaceutical supply
channel in human and animal health. With over $135 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 17,000 people. AmerisourceBergen is ranked #16 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

AmerisourceBergen’s Cautionary Note Regarding
Forward-Looking Statements

Certain of the statements contained in this press release are
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Words such as “expect,” “likely,” “outlook,” “forecast,” “would,”
“could,” “should,” “can,” “will,” “project,” “intend,” “plan,”
“continue,” “sustain,” “synergy,” “on track,” “believe,” “seek,”
“estimate,” “anticipate,” “may,” “possible,” “assume,” variations of
such words, and similar expressions are intended to identify such
forward-looking statements. These statements are based on management’s
current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance
and are based on assumptions that could prove incorrect or could cause
actual results to vary materially from those indicated. Among the
factors that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: competition;
industry consolidation of both customers and suppliers resulting in
increasing pressure to reduce prices for our products and services;
changes in pharmaceutical market growth rates; price inflation in
branded and generic pharmaceuticals, and price deflation in generics;
declining economic conditions in the United States and abroad; financial
market volatility and disruption; substantial defaults in payment,
material reduction in purchases by or the loss, bankruptcy or insolvency
of a major customer; the loss, bankruptcy or insolvency of a major
supplier; changes to the customer or supplier mix; the retention of key
customer or supplier relationships under less favorable economics or the
adverse resolution of any contract or other dispute with customers or
suppliers; interest rate and foreign currency exchange rate
fluctuations; the disruption of AmerisourceBergen’s cash flow and
ability to return value to its stockholders in accordance with its past
practices; risks associated with the strategic, long-term relationship
between Walgreen Boots Alliance, Inc. and AmerisourceBergen, including
with respect to the pharmaceutical distribution agreement and/or the
global sourcing joint venture; risks associated with the potential
impact on AmerisourceBergen’s earnings per share resulting from the
issuance of the warrants to subsidiaries of Walgreen Boots Alliance,
Inc. (the “Warrants”); AmerisourceBergen’s inability to implement its
hedging strategy to mitigate the potentially dilutive effect of the
issuance of its common stock in accordance with the Warrants under its
special share repurchase program due to its financial performance, the
current and future share price of its common stock, its expected cash
flows, competing priorities for capital, and overall market conditions;
changes in the United States healthcare and regulatory environment;
increasing governmental regulations regarding the pharmaceutical supply
channel and pharmaceutical compounding; federal and state government
enforcement initiatives to detect and prevent suspicious orders of
controlled substances and the diversion of controlled substances;
federal and state prosecution of alleged violations of related laws and
regulations, and any related litigation, including shareholder
derivative lawsuits or other disputes relating to our distribution of
controlled substances; increased federal scrutiny and qui tam litigation
for alleged violations of fraud and abuse laws and regulations and/or
any other laws and regulations governing the marketing, sale, purchase
and/or dispensing of pharmaceutical products or services and any related
litigation; material adverse resolution of pending legal proceedings;
declining reimbursement rates for pharmaceuticals; the possibility that
the merger with PharMEDium may not be completed in the anticipated time
frame, or at all; the acquisition of businesses that do not perform as
expected, or that are difficult to integrate or control, including the
integration of MWI and, if completed, PharMEDium, or the ability to
capture all of the anticipated synergies related thereto; managing
foreign expansion, including non-compliance with the U.S. Foreign
Corrupt Practices Act, anti-bribery laws and economic sanctions and
import laws and regulations; malfunction, failure or breach of
sophisticated information systems to operate as designed; risks
generally associated with data privacy regulation and the international
transfer of personal data; changes in tax laws or legislative
initiatives that could adversely affect AmerisourceBergen’s tax
positions and/or AmerisourceBergen’s tax liabilities or adverse
resolution of challenges to AmerisourceBergen’s tax positions; natural
disasters or other unexpected events that affect AmerisourceBergen’s
operations; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors affecting AmerisourceBergen’s
business generally. Certain additional factors that management believes
could cause actual outcomes and results to differ materially from those
described in forward-looking statements are set forth (i) in Item 1A
(Risk Factors) and Item 1 (Business) in the Company’s Annual Report on
Form 10-K for the fiscal year ended September 30, 2014 and elsewhere in
that report and (ii) in other reports filed with the Securities and
Exchange Commission.

Contacts

AmerisourceBergen Corporation
Barbara Brungess,
610-727-7199

bbrungess@amerisourcebergen.com